DE69532766D1 - Plasmid für il-2 expression - Google Patents

Plasmid für il-2 expression

Info

Publication number
DE69532766D1
DE69532766D1 DE69532766T DE69532766T DE69532766D1 DE 69532766 D1 DE69532766 D1 DE 69532766D1 DE 69532766 T DE69532766 T DE 69532766T DE 69532766 T DE69532766 T DE 69532766T DE 69532766 D1 DE69532766 D1 DE 69532766D1
Authority
DE
Germany
Prior art keywords
expression
sequence
plasmid
facilitating
sequence derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69532766T
Other languages
English (en)
Other versions
DE69532766T2 (de
Inventor
M Hobart
Michal Margalith
E Parker
Shirin Khatibi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresh Tracks Therapeutics Inc
Original Assignee
Vical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vical Inc filed Critical Vical Inc
Publication of DE69532766D1 publication Critical patent/DE69532766D1/de
Application granted granted Critical
Publication of DE69532766T2 publication Critical patent/DE69532766T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
DE69532766T 1994-11-28 1995-11-28 Plasmid für il-2 expression Expired - Lifetime DE69532766T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US345913 1994-11-28
US08/345,913 US5641665A (en) 1994-11-28 1994-11-28 Plasmids suitable for IL-2 expression
PCT/US1995/015020 WO1996017063A1 (en) 1994-11-28 1995-11-28 Plasmids suitable for il-2 expression

Publications (2)

Publication Number Publication Date
DE69532766D1 true DE69532766D1 (de) 2004-04-29
DE69532766T2 DE69532766T2 (de) 2005-03-10

Family

ID=23357068

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69532766T Expired - Lifetime DE69532766T2 (de) 1994-11-28 1995-11-28 Plasmid für il-2 expression

Country Status (7)

Country Link
US (5) US5641665A (de)
EP (2) EP0795015B1 (de)
JP (1) JP3710815B2 (de)
AT (1) ATE262588T1 (de)
CA (1) CA2205910C (de)
DE (1) DE69532766T2 (de)
WO (1) WO1996017063A1 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867195B1 (en) * 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US7105574B1 (en) 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US6034072A (en) * 1997-02-10 2000-03-07 Genemedicine, Inc. IL-2 gene expression and delivery systems and uses
US6051428A (en) * 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
GB2324960A (en) * 1997-05-09 1998-11-11 Univ Manchester Delivery of naked DNA for wound healing
ATE550042T1 (de) * 1997-11-20 2012-04-15 Vical Inc Behandlung von krebs mithilfe cytokin- exprimierender polynukleotide und zusammensetzungen dafür
WO1999047678A2 (en) * 1998-03-19 1999-09-23 Valentis, Inc. Interferon alpha plasmids and delivery systems, and methods of making and using the same
AUPP655698A0 (en) 1998-10-16 1998-11-05 Commonwealth Scientific And Industrial Research Organisation Delivery system for porcine somatotropin
WO2000040273A2 (en) * 1999-01-08 2000-07-13 Vical Incorporated Treatment of viral diseases using an interferon omega expressing polynucleotide
ATE549032T1 (de) * 1999-03-26 2012-03-15 Vical Inc Adjuvanzverbindungen zur verbesserung von immunreaktionen auf polynukleotid-basierten impfstoffen
WO2001027156A1 (en) * 1999-10-08 2001-04-19 Curagen Corporation Interleukin-2 like protein and nucleic acids encoding same
CA2389633A1 (en) * 1999-11-01 2001-05-10 Chiron Corporation Expression vectors, transfection systems, and method of use thereof
EP1278551A2 (de) * 2000-04-21 2003-01-29 Vical Incorporated Zusammensetzungen und verfahren zur (in vivo) verabreichung der auf polynukleotiden-basierenden therapeutika
AU2001268716A1 (en) * 2000-06-23 2002-01-08 Maxygen, Inc. Novel chimeric promoters
AU2002254174A1 (en) * 2001-03-13 2002-09-24 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
US20030003074A1 (en) * 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
US20060159657A1 (en) * 2001-06-14 2006-07-20 Macromed, Incorporated Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
DE02786364T1 (de) * 2001-10-01 2005-01-13 Diversa Inc., San Diego Konstruktion ganzer zellen unter verwendung einer echtzeitanalyse des metabolischen flusses
WO2003029425A2 (en) * 2001-10-01 2003-04-10 Diversa Corporation Whole cell engineering using real-time metabolic flux analysis
AU2002359522A1 (en) * 2001-11-28 2003-06-10 Applera Corporation Compositions and methods of selective nucleic acid isolation
EP1572908A4 (de) * 2002-02-14 2008-10-22 William J Rutter Chimäre moleküle zur spaltung in einem behandelten wirt
US6923958B2 (en) * 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
US7435545B2 (en) * 2002-05-01 2008-10-14 Applera Corporation Method for sizing polynucleotides using electrophoresis with non-DNA size standards
AU2003295502A1 (en) 2002-11-12 2004-06-03 Yucheng Chang Adenoviral vector vaccine
EP1581201A4 (de) * 2002-12-23 2011-03-30 Vical Inc Verfahren zur herstellung steriler arzneimittel auf polynukleotidbasis
JP4917263B2 (ja) * 2002-12-23 2012-04-18 バイカル インコーポレイテッド 核酸／ブロックコポリマー／陽イオン性界面活性剤複合体を凍結乾燥する方法
WO2004080404A2 (en) * 2003-03-07 2004-09-23 University Of Utah Research Foundation Il-2 transmembrane constructs
US8299229B2 (en) 2003-11-24 2012-10-30 Microvax, Llc Mucin antigen vaccine
US8828957B2 (en) * 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
US7504243B2 (en) 2004-03-19 2009-03-17 The United States Of America As Represented By The Department Of Health And Human Services Methods for the production of biliverdin
US20060134221A1 (en) * 2004-12-03 2006-06-22 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
EP2634252B1 (de) 2005-02-11 2018-12-19 University of Southern California Verfahren zur Expression von Proteinen mit Disulfidbrücken
US7691579B2 (en) * 2005-04-15 2010-04-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006130525A2 (en) * 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
WO2007056266A2 (en) * 2005-11-07 2007-05-18 Sidney Kimmel Cancer Center Cd40 ligand fusion protein vaccine
EP2029156A4 (de) 2006-05-01 2010-07-21 Univ Southern California Kombinationstherapie zur krebsbehandlung
CA2658484A1 (en) * 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
WO2008074678A1 (en) 2006-12-18 2008-06-26 F. Hoffmann-La Roche Ag Novel use of inhibitors of soluble epoxide hydrolase
US20080299182A1 (en) * 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2248903A1 (de) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Verfahren und Reagenzien zum effizienten und gezielten Gentransfer in Monozyten und Makrophagen
AU2010326132B9 (en) 2009-12-01 2014-10-02 Translate Bio, Inc. Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP4108671A1 (de) 2010-10-01 2022-12-28 ModernaTX, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und ihre verwendungen
US8853377B2 (en) 2010-11-30 2014-10-07 Shire Human Genetic Therapies, Inc. mRNA for use in treatment of human genetic diseases
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
KR102128248B1 (ko) 2011-06-08 2020-07-01 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103974724B (zh) 2011-10-03 2019-08-30 现代泰克斯公司 修饰的核苷、核苷酸和核酸及其用途
CA2859387A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
JP6144355B2 (ja) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 化学修飾ｍＲＮＡ
KR20150128687A (ko) 2013-03-14 2015-11-18 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna의 정제 방법
BR112015022868B1 (pt) 2013-03-14 2023-05-16 Ethris Gmbh Composições de mrna de cftr e usos e métodos relacionados
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
EP3501605B1 (de) 2013-10-22 2023-06-28 Translate Bio, Inc. Mrna-therapie für argininosuccinat-synthase-mangel
EP3060258A1 (de) 2013-10-22 2016-08-31 Shire Human Genetic Therapies, Inc. Mrna-therapie für phenylketonurie
AU2015249312B2 (en) 2014-04-25 2021-07-29 Translate Bio, Inc. Methods for purification of messenger RNA
EP2940128A1 (de) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus mit einem albuminbindenden Teil
EP3585417B1 (de) 2017-02-27 2023-02-22 Translate Bio, Inc. Methode der herstellung von codon-optimierter cftr-mrna
CA3063531A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
WO2020041793A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
WO2023034728A1 (en) * 2021-08-30 2023-03-09 Carrygenes Bioengineering, Llc Synthetic chromosome encoding two or more chimeric antigen receptors binding to tumor associated antigens

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB219038A (de)
EP0091539B2 (de) * 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Das Polypeptid Interleukin-2 kodierendes Gen, rekombinante, dieses Gen enthaltende DNA, diese rekombinante DNA aufweisende Zelllinien und Verfahren zur Herstellung von Interleukin-2 unter Verwendung der genannten Zellen
EP0173552B1 (de) * 1984-08-24 1991-10-09 The Upjohn Company Rekombinante DNA-Verbindungen und Expression von Polypeptiden wie tPA
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4992367A (en) * 1986-05-12 1991-02-12 Hoffmann-La Roche Inc. Enhanced expression of human interleukin-2 in mammalian cells
GB8717430D0 (en) * 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6214804B1 (en) * 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6867195B1 (en) * 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US6228844B1 (en) * 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US6706694B1 (en) * 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US5681562A (en) * 1991-06-25 1997-10-28 Sidney Kimmel Cancer Center Lymphokine gene therapy of cancer
US5229109A (en) * 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
CA2134773A1 (en) * 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US5641665A (en) * 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
WO1997019675A2 (en) * 1995-11-30 1997-06-05 Vical Incorporated Complex cationic lipids
US6034072A (en) 1997-02-10 2000-03-07 Genemedicine, Inc. IL-2 gene expression and delivery systems and uses
ATE549032T1 (de) * 1999-03-26 2012-03-15 Vical Inc Adjuvanzverbindungen zur verbesserung von immunreaktionen auf polynukleotid-basierten impfstoffen
US6696424B1 (en) * 1999-05-28 2004-02-24 Vical Incorporated Cytofectin dimers and methods of use thereof

Also Published As

Publication number Publication date
WO1996017063A1 (en) 1996-06-06
CA2205910C (en) 2010-02-09
JP3710815B2 (ja) 2005-10-26
US6147055A (en) 2000-11-14
EP0795015B1 (de) 2004-03-24
EP0795015A1 (de) 1997-09-17
US20030203863A1 (en) 2003-10-30
CA2205910A1 (en) 1996-06-06
DE69532766T2 (de) 2005-03-10
US6399588B1 (en) 2002-06-04
EP1433855A3 (de) 2004-11-17
ATE262588T1 (de) 2004-04-15
US5641665A (en) 1997-06-24
US20050065107A1 (en) 2005-03-24
EP1433855A2 (de) 2004-06-30
JPH10509877A (ja) 1998-09-29

Similar Documents

Publication Publication Date Title
DE69532766D1 (de) Plasmid für il-2 expression
IL136189A0 (en) Erythropoietin analogs
AU1865397A (en) Transferrin receptor genes of moraxella
WO1994003616A3 (fr) Vecteur de clonage et/ou de sequençage
AU1094892A (en) Improved activation of recombinant proteins
BR9607583B1 (pt) plasmìdios procarióticos recombinantes.
DE69133048T2 (de) Tapetumspezifische promotoren aus brassicaceae spp.
DE69233031D1 (de) Hefepromotor und seine verwendung
EP0396741A4 (en) Dna encoding lys?46 , asp?97 , asp?113 ) and lys?46 , asp?113 , asp?137 ) thaumatin i polypeptides
ES2113948T3 (es) Promotor de levadura y su utilizacion.
ATE71148T1 (de) Dns-kodierendes (asp 113> und (lys 46, asp 113> thaumatin-i.
EP0352707A3 (de) Expressionssystem für die Sekretion von bioaktivem, menschlichem granulozyt-makrophagem Koloniestimulierungsfaktor (GM-CSF) und anderen heterologen Proteinen aus Streptomyces
AU8219991A (en) Recombinant secretable fusion proteins

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition